Alleviant ALLAY-HFrEF Study

计划入组 350 人 · 首次发布于 2025 年 2 月 6 日

Alleviant ALLAY-HF Study

计划入组 700 人 · 首次发布于 2023 年 1 月 17 日

Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap

计划入组 20 人 · 首次发布于 2025 年 4 月 8 日

ATX-501 (Allay Therapeutics)

ATX-201

ATX-101

Allay Therapeutics, Inc.

United States

JASPER THERAPEUTICS, INC

United States

CRISPR Therapeutics, Inc.

United States

Allay Therapeutics' ATX101 Receives FDA Breakthrough Therapy Designation for Post-Surgical Pain Relief After Total Knee Arthroplasty

Allay Therapeutics Secures $57.5M Series D to Advance Ultra-Sustained Pain Management Platform

Postoperative Pain Pipeline 2026: Over 40 Companies Advance Novel Therapies with Extended-Release and Non-Opioid Candidates